Human papilloma virus type 51 L1 protein mutants
US12097251B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Sep 26, 2019 |
| Grant date | Sep 24, 2024 |
| Priority date | — |
| Expiry date | Jul 29, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/20034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are a mutated HPV51 L1 protein or a variant thereof, a coding sequence thereof, a preparation method therefor, and a virus-like particle containing same, wherein the protein or the variant and the virus-like particle thereof are capable of inducing neutralizing antibodies against at least two types of HPV (for example, HPV51 and HPV69, or HPV51, HPV69 and HPV26). Also provided is the use of the above-mentioned protein and the virus-like particle for preparing a pharmaceutical composition or a vaccine, wherein the pharmaceutical composition or the vaccine can be used to prevent infections of the at least two types of HPV and diseases caused by the infections, such as cervical cancer and condyloma acuminatum.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.